A chemical patent, pharmaceutical patent or drug patent is a patent for an invention in the chemical or pharmaceuticals industry. Strictly speaking, in most jurisdictions, there are essentially no differences between the legal requirements to obtain a patent for an invention in the chemical or pharmaceutical fields, in comparison to obtaining a patent in the other fields, such as in the mechanical field. A chemical patent or a pharmaceutical patent is therefore not a sui generis right, i.e. a special legal type of patent.
In the pharmaceutical industry, the patent protection of drugs and medicines is accorded a particular importance, because drugs and medicines can easily be copied or imitated (by analyzing a pharmaceutical substance) and because of the significant research and development spending and the high risks associated with the development of a new drug.[1][2][3]
Chemical patents are different from other sources of technical information because of the generic, Markush structures contained within them, named after the inventor Eugene Markush who won a claim in the US in 1925 to allow such structures to be used in patent claims. These generic structures are used to make the patent claim as broad as possible.
Patent law |
---|
Overviews |
Basic concepts |
Patentability |
Additional requirements |
By region / country |
By specific subject matter |
|
See also |
See also
- Compulsory licensing (patents)
- Criticism of pharmaceutical patents
- Evergreening
- Generic drug
- Supplementary protection certificate
References
- Oliver Gassmann, Gerrit Reepmeyer, Maximilian von Zedtwitz, Leading Pharmaceutical Innovation, Trends and Drivers for Growth in the Pharmaceutical Industry, Springer, 2008, ISBN 3-540-77635-4, ISBN 978-3-540-77635-2, pages 133-134.
- Scherer FM., The economics of human gene patents, Acad Med. 2002 Dec;77(12 Pt 2):1348-67 : "
Further reading
- European Commission, Pharmaceuticals, Sector Inquiry, 2008 (Public Consultation, Preliminary Report).
- "Patents and Pharmaceuticals", a paper given on 29 November 2008 at the Presentation of the Directorate-General of Competition’s Preliminary Report of the Pharma-sector inquiry, by the Rt. Hon. Sir Robin Jacob
- India wins landmark patent battle, BBC News, March 9, 2005
- "HIV/AIDS, Patents and the TRIPS Agreement: Issues and Options", United States Congressional Research Service, July 27, 2001
- "Pharmaceutical Patent Term Extensions: A Brief Explanation", United States Congressional Research Service, January 31, 2002
External links[edit]
- Patent Opposition Database, an online resource launched by Doctors without Borders as "a tool which can be used to explore how to challenge unfair patents and their negative impact on access to medicines." ("About". Patent Opposition Database. MSF Access Campaign. Retrieved October 13, 2012.)
SHIMOGA, KARNATAKA, INDIA
Shimoga - Wikipedia, the free encyclopedia
en.wikipedia.org/wiki/Shimoga
.
Shimoga–Talaguppa railway
Kundadri, Shimoga
Shimoga Photos - Kudli Temple
Ornate baluster in Thripuranthakeshwara temple at Balligavi, Shimoga district.jpg
sigandur - Shimoga
////////